Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug developer Pro-Pharmaceuticals has obtained encouraging results from preclinical experiments, showing that its anticancer treatment, Davanat, can enhance the anti-tumor activity of Roche and Genentech's Avastin plus 5-FU chemotherapy.
Subscribe to our email newsletter
The preclinical data reveals that, when Davanat is co-administrated with 5-FU and the anti-vascular endothelial growth factor (VEGF) drug, Avastin, to mice implanted with human colon tumor (COLO 205), Davanat significantly improves anti-tumor activities of the combination and doubles the tumor shrinkage rate.
“We saw significant improved anti-tumor activity when co-administering Davanat with Avastin/5-FU as compared with Avastin/5-FU,” said Dr Anatole Klyosov, consulting chief scientist at Pro-Pharmaceuticals. “These results are encouraging and warrant further investigation.”
The data is being presented at the third Annual Glycomics and Carbohydrates in Drug Development Conference in La Jolla, California.
Davanat is a proprietary polysaccharide in a Carbosome formulation that enables the targeted delivery of chemotherapy drugs to protein receptors (lectins) that are unique to cancer cells.
Shares in Pro-Pharmaceuticals had risen by close by 8% following the announcement of these results.